ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
11.00
-0.39 (-3.42%)
Dec 5, 2025, 4:00 PM EST - Market closed
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 115 employees as of December 31, 2024. The number of employees increased by 15 or 15.00% compared to the previous year.
Employees
115
Change (1Y)
15
Growth (1Y)
15.00%
Revenue / Employee
n/a
Profits / Employee
-$1,176,261
Market Cap
1.07B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Dec 31, 2021 | 78 | 17 | 27.87% |
| Dec 31, 2020 | 61 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ORIC News
- 8 hours ago - ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 - GlobeNewsWire
- 11 hours ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 day ago - ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 - GlobeNewsWire
- 1 day ago - ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 - GlobeNewsWire
- 2 days ago - ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 - GlobeNewsWire
- 2 days ago - Top 3 Health Care Stocks That May Rocket Higher In December - Benzinga
- 4 days ago - ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 - GlobeNewsWire
- 11 days ago - ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire